Involving A Nucleic Acid Encoding A Protein Related To The Nervous System, (e.g., Nerve Related Factors, Brain-derived Cytokines, Nerve Cell Biomarker, Etc.) Patents (Class 435/6.16)
-
Patent number: 9804153Abstract: A method for magnetic cellular manipulation may include contacting a composition with a biological sample to form a mixture. The composition may include a plurality of particles. Each particle in the plurality of particles may include a magnetic substrate. The magnetic substrate may be characterized by a magnetic susceptibility greater than zero. The composition may also include a chargeable silicon-containing compound. The chargeable silicon-containing compound may coat at least a portion of the magnetic substrate. The biological sample may include cells and/or cellular structures. The method may also include applying a magnetic field to the mixture to manipulate the composition.Type: GrantFiled: August 23, 2013Date of Patent: October 31, 2017Assignee: Inguran, LLCInventor: Kristie Marie Krug
-
Patent number: 9797894Abstract: The invention relates to methods for conducting binding assays in an assay device that includes one or more storage and use zone. The storage zones of the assay device are configured to house one or more reagents used in an assay conducted in the use zone of the device.Type: GrantFiled: August 1, 2013Date of Patent: October 24, 2017Assignee: Meso Scale Technologies, LLC.Inventors: Sudeep Kumar, George Sigal, Michael Tsionsky
-
Patent number: 9797912Abstract: The invention relates to a method of diagnosing or assessing an inflammatory bowel disease in a subject, comprising comparing the level of one or more markers in a tissue or body fluid of the subject relative to a reference value for the one or more markers, wherein the marker is selected from the group consisting of Secretogranin-1 or a fragment thereof, guanylin or a fragment thereof, SPP 24 or a fragment thereof, AMBP or a fragment thereof; and serglycin or a fragment thereof.Type: GrantFiled: June 27, 2014Date of Patent: October 24, 2017Assignee: NEWSOUTH INNOVATIONS PTY LIMITEDInventors: Valerie Christine Wasinger, Rupert Wing-Loong Leong
-
Patent number: 9797017Abstract: The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer. The use of the diagnostic kit or nucleic acid chip of the invention enables diagnosis of bladder cancer at an early stage of transformation, thus enabling early diagnosis of bladder cancer, and can diagnose bladder cancer in a more accurate and rapid manner compared to a conventional method.Type: GrantFiled: May 3, 2017Date of Patent: October 24, 2017Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Young Ho Moon, Tae Jeong Oh
-
Patent number: 9797002Abstract: Disclosed are methods and kits for genome-wide methylation of GpC sites and for genome-wide chromatin structural determination. Specifically, the methods and kits of the present invention make possible the simultaneous determination of endogenous DNA methylation state and chromatin architecture across the entire genome.Type: GrantFiled: June 27, 2011Date of Patent: October 24, 2017Assignee: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Theresa K. Kelly, Gangning Liang, Peter A. Jones
-
Patent number: 9790559Abstract: The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.Type: GrantFiled: April 20, 2017Date of Patent: October 17, 2017Assignee: Guardant Health, Inc.Inventor: AmirAli Talasaz
-
Patent number: 9790558Abstract: Methods for detecting cancer that include hybridizing a set of chromosomal probes to a biological sample obtained from a patient, and identifying if aneusomic cells are present in a selected subset of cells obtained from the biological sample are described. A set of chromosomal probes and kits for detecting cancer that include sets of chromosomal probes, are also described.Type: GrantFiled: June 1, 2015Date of Patent: October 17, 2017Assignees: Mayo Foundation for Medical Education and Research, Abbott Molecular Inc.Inventors: Kevin C. Halling, Robert B. Jenkins, Walter King, Irina A. Sokolova, Steven A. Seelig
-
Patent number: 9791447Abstract: Provided herein are methods of detecting binding of an SENP1 polypeptide to a compound and methods for screening for inhibitors of SENP1. Further provided are aqueous compositions comprising SENP1 polypeptides and NMR apparatuses comprising the compositions for NMR analysis.Type: GrantFiled: April 7, 2014Date of Patent: October 17, 2017Assignee: City of HopeInventor: Yuan Chen
-
Patent number: 9783857Abstract: The present invention relates to a kit and nucleic acid chip for diagnosing bladder cancer using a bladder cancer-specific marker gene. More particularly, the invention relates to a kit and nucleic acid chip for diagnosing bladder cancer, which can detect the promoter methylation of a bladder cancer-specific gene, the promoter or exon region of which is methylated specifically in transformed cells of bladder cancer. The use of the diagnostic kit or nucleic acid chip of the invention enables diagnosis of bladder cancer at an early stage of transformation, thus enabling early diagnosis of bladder cancer, and can diagnose bladder cancer in a more accurate and rapid manner compared to a conventional method.Type: GrantFiled: May 3, 2017Date of Patent: October 10, 2017Assignee: GENOMICTREE, INC.Inventors: Sung Whan An, Young Ho Moon, Tae Jeong Oh
-
Patent number: 9778263Abstract: The present disclosure relates to characterization of biological samples. By way of example, a biological sample may be contacted with a plurality of probes specific for targets in the sample, such as probes for immune markers and segmenting probes. Acquired image data of the sample may be used to segment the images into epithelial and stromal regions to characterize individual cells in the sample based on the binding of the probes. Further, the biological sample may be characterized by a distribution, location, and type of a plurality of the characterized cells.Type: GrantFiled: November 13, 2013Date of Patent: October 3, 2017Assignee: General Electric CompanyInventors: Srabani Bhaumik, Michael John Gerdes, Zhengyu Pang, Fiona Ginty, Christopher James Sevinsky, Qing Li, Alberto Santamaria-Pang, Yunxia Sui, Keyur Hemantkumar Desai
-
Patent number: 9771611Abstract: The invention relates to a method for detecting several different chromosomes or DNA regions in a cell in order to provide evidence for structural chromosomal aberrations, wherein the chromosomal aberrations have at least two breaking point regions within a chromosome, on the basis of directly or indirectly labeled nucleic acid fragments (probes), wherein: a first probe labeled with label A (probe A) and a second probe labeled with label B (probe B) flank a breaking point region 1, and form the fusion signals A-B; and two probes, a third and a fourth, each labeled with a label C (probes C), flank a breaking point region 2, and form the fusion signals C-C, wherein the above-mentioned fusion signals change in the event of a chromosomal aberration to fusion signals A-C and to fusion signals B-C.Type: GrantFiled: April 27, 2012Date of Patent: September 26, 2017Assignee: Zytovision GmbHInventor: Sven Hauke
-
Patent number: 9771617Abstract: The invention provides a method of diagnosing Alzheimer's Disease in a subject, by determining the level of at least one miRNA in a sample derived from the subject, wherein a change in the level of the at least one miRNA relative to a suitable control is indicative of Alzheimer's Disease in the subject. Methods for monitoring the course of Alzheimer's Disease, methods of treating a subject having Alzheimer's Disease, and kits for diagnosing Alzheimer's Disease are also provided.Type: GrantFiled: June 26, 2012Date of Patent: September 26, 2017Assignee: Eisai R&D Management Co., Ltd.Inventors: Zoltan Dezso, Pavan Kumar
-
Patent number: 9763970Abstract: Disclosed are nutritional compositions including human milk oligosaccharides and nucleotides that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.Type: GrantFiled: December 22, 2011Date of Patent: September 19, 2017Assignee: ABBOTT LABORATORIESInventors: Rachael Buck, Debra L. Thomas, Joseph P. Schaller
-
Patent number: 9752176Abstract: Methods and devices relate to the isolation of nucleic acids of interest from within a population of nucleic acids such as libraries of nucleic acid sequences.Type: GrantFiled: June 15, 2012Date of Patent: September 5, 2017Assignee: Ginkgo Bioworks, Inc.Inventors: Li-yun A. Kung, Daniel Schindler, Joseph Jacobson
-
Patent number: 9752192Abstract: Mutations located within the gene encoding the homeobox transcription factor, ENGRAILED 2 (EN2), have now been identified as molecular markers associated with susceptibility for autism and related disorders. Thus, the present invention relates to compositions in the form of diagnostic kits, primers and target sequences, for use in methods for determining the predisposition, the onset or the presence of autism spectrum disorder in a mammal. Moreover, therapeutic methods for treating a person inflicted with, or predisposed to, an autism spectrum disorder based upon modulating the level or activity of EN2 are also provided.Type: GrantFiled: March 8, 2013Date of Patent: September 5, 2017Assignee: Rutgers, The State University of New JerseyInventors: James H. Millonig, Linda Brzustowicz, Neda Gharani
-
Patent number: 9752154Abstract: This invention is related to methods and systems for vector assembly for transgenic plants. A uniform modular process is used to reduce cycle time and the methods and systems provided herein can increase cloning throughput using multiple-well plates, for example 96-well plates. In some embodiments, the methods and systems provided herein eliminate or reduce the need for sequencing confirmation because no PCR is involved in the vector assembly process.Type: GrantFiled: July 23, 2013Date of Patent: September 5, 2017Assignee: Dow AgroSciences LLCInventors: Sandeep Kumar, Steven L. Evans, Manju Gupta
-
Patent number: 9756193Abstract: A distance between a reference position and a reference image of a sheet is accurately measured without adding a special device even when an attitude of the sheet is not stable. An aspect of the present invention obtains image data by reading a sheet surface formed with the reference image such as a trim mark by a reading portion. A height calculation portion calculates edge-blur amounts of the reference position and the reference image on the sheet surface from the image data. Furthermore, a height calculation portion detects heights from a focus position to the sheet surface for the reference position and the reference image, from the edge-blur amount and a reflected light amount of a white solid portion. Moreover, a distance detection portion calculates a distance between the reference position and the reference image on the sheet surface, on the basis of a detection result.Type: GrantFiled: April 29, 2016Date of Patent: September 5, 2017Assignee: KONICA MINOLTA, INC.Inventors: Aiko Kubota, Daiki Yamanaka
-
Patent number: 9746470Abstract: In some aspects, the invention provides methods of identifying, detecting, and/or measuring protein-protein interactions. In some aspects, the invention provides methods of identifying and/or characterizing modulators of protein-protein interactions. In some aspects, the invention provides methods of identifying and/or characterizing modulators of protein activity, wherein the methods are based at least in part on measuring interaction between a chaperone and client protein. In some aspects, the invention provides methods for identifying and/or characterizing compounds and/or for assessing compound specificity, wherein the methods are based at least in part on measuring interaction between a chaperone and client protein. In some embodiments, a client protein is a kinase. In some embodiments, a compound is a kinase inhibitor. In some aspects, the invention provides methods of profiling kinase inhibitor specificity.Type: GrantFiled: May 9, 2012Date of Patent: August 29, 2017Assignee: Whitehead Institute for Biomedical ResearchInventors: Mikko Taipale, Susan Lindquist
-
Patent number: 9746481Abstract: The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing brain injuries. Brain injury can include overt or traumatic brain injury, as well as subclinical brain injury (SCI). In one embodiment, a method for diagnosing SCI in a patient comprises (a) collecting a sample from the patient; (b) measuring the levels of a panel of biomarkers in the sample collected from the patient, wherein the panel of biomarkers comprises ASTN1, BAI3, CNDP1, ERMIN, GFAP, GRM3, KLH32, MAGE2, NRG3, NRGN, OMG, SLC39A12, RTN1, and MT3; and (c) comparing the levels of the panel of biomarkers with predefined levels of the same panel of biomarkers that correlate to a patient having SCI and predefined levels of the same panel of biomarkers that correlate to a patient not having SCI, wherein a correlation to one of the predefined levels provides the diagnosis.Type: GrantFiled: October 14, 2011Date of Patent: August 29, 2017Assignee: The Johns Hopkins UniversityInventors: Allen Dale Everett, James Francis Casella, Jennifer Van Eyk
-
Patent number: 9746458Abstract: Methods and kits for identifying neurological conditions in a patient by determining a level of expression of dynactin subunit p62 are disclosed. The neurological conditions may include, for example, Alzheimer's Disease (AD) without cerebral amyloid angiopathy (CAA).Type: GrantFiled: April 26, 2012Date of Patent: August 29, 2017Assignee: Loma Linda University Medical CenterInventors: Wolff M. Kirsch, Matthew Schrag, Andrew Crofton, Matthew Zabel, Claudius Mueller
-
Patent number: 9733222Abstract: The subject technology is directed to a CO2-based chromatography system and method for rapid determination of the levels and/or the presence or absence of steroids or steroid derivatives in a sample.Type: GrantFiled: October 2, 2013Date of Patent: August 15, 2017Assignee: Waters Technologies CorporationInventors: Christopher J. Hudalla, Jacob N. Fairchild, Jason F. Hill
-
Patent number: 9732320Abstract: The embodiments provide for the modulation of both the differentiation and activity of human TH17 cells. More specifically, human TH17 cell differentiation can modulated by TGF-? and IL-21, and their agonists and antagonists. Function of TH17 cells can be modulated by, for example, BLT1 or podoplanin, and their agonists and antagonists. Additionally, the embodiments provide for the identification of TH17 cells. More specifically, human TH17 cells specifically upregulate BLT1 and podoplanin.Type: GrantFiled: October 17, 2014Date of Patent: August 15, 2017Assignee: The Brigham and Women's Hospital, Inc.Inventors: Vijay K. Kuchroo, David E. Anderson, Estelle Bettelli, David Hafler, Mohammed Oukka
-
Patent number: 9727691Abstract: The present invention provides a method for evaluating (predicting, etc.) an individual difference (the tendency of every individual) in terms of drug sensitivity and disease vulnerability, comprising using a gene polymorphism of a cyclic AMP responsive element binding protein gene or the like. The method for evaluating drug sensitivity and the method for evaluating disease vulnerability according to the present invention comprise associating a gene polymorphism of a cyclic AMP responsive element binding protein gene or a haplotype constituted by the gene polymorphism with the drug sensitivity and disease vulnerability of an individual.Type: GrantFiled: October 1, 2012Date of Patent: August 8, 2017Inventors: Kazutaka Ikeda, Daisuke Nishizawa, Kenichi Fukuda
-
Patent number: 9725757Abstract: The present invention relates to compositions and methods for the detection of target molecules, and the amplification of detectable signals generated by detection assays. More specifically, the present invention relates to methods utilizing catalytic nucleic acid enzymes to generate and/or amplify a signal indicative of the presence of target molecules (e.g. nucleic acids and proteins), and compositions for use in the methods.Type: GrantFiled: June 18, 2013Date of Patent: August 8, 2017Assignee: SPEEDX PTY LTDInventors: Simon Mark Bone, Alison Velyian Todd, Timothy Daniel Meehan
-
Patent number: 9719128Abstract: The present invention features methods for selective lysis of endogenous cells in a biological sample. In preferred embodiments, the methods of the invention comprise contacting the biological sample with lysis solution, and subjecting the mixture to ultrasound, thereby selectively lysing the endogenous cells in the biological sample. The invention also features a lysis solution comprising Saponin and Proteinase.Type: GrantFiled: November 19, 2013Date of Patent: August 1, 2017Assignee: AdvanDx, Inc.Inventors: Martin Fuchs, Michelle Meltzer
-
Patent number: 9714454Abstract: The present invention relates to detection of materials derived from transgenic plant events. In particular, the invention provides methods, reagents, kits and reference materials for detecting the presence or absence in a sample of genetic material derived from and attributable to select transgenic plant events.Type: GrantFiled: February 7, 2014Date of Patent: July 25, 2017Assignee: Scientific Institute of Public HealthInventors: Marc Henri Germain Van Den Bulcke, Antoon Piet Nelly Raoul Lievens, Amaya Leunda, Etondoh Guillaume Mbongolo Mbella, Elodie Barbau-Piednoir, Myriam Jacqueline Sylviane Sneyers
-
Patent number: 9695252Abstract: Disclosed herein are recombinant protein scaffolds and recombinant multifunctional protein scaffolds for use in producing antigen-binding proteins In addition, nucleic acids encoding such recombinant protein scaffolds, recombinant multifunctional protein scaffolds, and antigen-binding proteins are provided Vectors and cells useful for expression of the described proteins are also provided, as are methods of use.Type: GrantFiled: April 2, 2014Date of Patent: July 4, 2017Assignee: The Trustees Of The University Of PennsylvaniaInventors: Mark I. Greene, Hongtao Zhang, Xiaomin Song, Ramachandran Murali, Masahide Tone
-
Patent number: 9694049Abstract: Disclosed herein are methods for diagnosing, prognosing and treating muscular dystrophy. The disclosed methods can be used to diagnosis, prognosis or treat a subject with merosin-deficient congenital muscular dystrophy Type 1A (MDC1A), limb-girdle muscular dystrophy (LGMD), facioscapulohumeral (FHMD), Beckers muscular dystrophy (BMD) or Duchenne muscular dystrophy (DMD). Also disclosed are methods of determining the effectiveness of an agent for the treatment of muscular dystrophy. In an example, a method of diagnosing or prognosing a subject with muscular dystrophy includes detecting expression of Galectin-1 or Galectin-3 in a sample obtained from the subject at risk of having or having one or more signs or symptoms associated with muscular dystrophy, thereby diagnosing or prognosing the subject with muscular dystrophy. Also provided are methods of enhancing muscle regeneration, repair, or maintenance in a subject by administering galectin, such as Galectin-1 and/or Galectin-3 to a subject in need thereof.Type: GrantFiled: August 10, 2012Date of Patent: July 4, 2017Assignee: BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNITVERSITY OF NEVADA, RENOInventors: Dean Burkin, Ryan Wuebbles, Pam Van Ry
-
Patent number: 9689044Abstract: Provided herein are MiIP-Seq assays and methods for detecting and/or identifying an immune-stimulating microbe in a patient sample. Also provided herein are methods for diagnosing an infectious disease or identifying a previously uncharacterized microbe in a patient sample. The methods and assays described herein are advantageous over existing methods in that they (i) do not require a culture step for microbe expansion, (ii) are not specific for a particular microbe and can be used to identify a previously uncharacterized microbe, and (iii) permits rapid processing due to the lack of a microbe culture step.Type: GrantFiled: January 26, 2012Date of Patent: June 27, 2017Assignee: The Brigham and Women's Hospital, Inc.Inventors: Richard S. Blumberg, Arthur Kaser
-
Patent number: 9683939Abstract: A system and method that images biological samples and uses chromophores to analyze the imaged samples. The chromophore analysis can be done by itself or in conjunction with fluorophore analysis in High Content Imaging systems. To perform chromophore analysis the biological samples can be labeled with different chromophores and imaged using transmitted light that is at least partially absorbed by the chromophores. To also perform fluorophore analysis the samples can also be labeled with fluorophores that are excited by excitation light. The chromophore analysis and fluorophore analysis can be performed separately or concurrently using a High Content Imaging system. The system provides the expanded capability by illuminating the chromophore-labeled samples with transmitted light of different wavelengths and automatically detecting the images which represent the differential absorption of the colored lights by the sample.Type: GrantFiled: May 11, 2015Date of Patent: June 20, 2017Assignee: CELLOMICS, INC.Inventors: Richik Niloy Ghosh, Dirk John VandenBerg, III, Keith Rao Heffley, Monica Jo Tomaszewski, Jeffrey Robert Haskins
-
Patent number: 9683231Abstract: The invention is directed to a method of characterizing a mechanism of action of an agent (e.g., a chemotherapeutic agent, a genotoxic agent). The method comprises contacting a plurality of populations of cells with an agent to be assessed, wherein each population of cells have one gene of interest targeted by a small hairpin RNA (shRNA) and wherein said gene of interest regulates cell death and a plurality of genes that regulate cell death are targeted in the plurality of populations of cells. A responsiveness of each population of cells to the agent is determined, thereby obtaining an shRNA signature of the agent, so as to identify one or more genes that mediate a response to the agent, thereby characterizing the mechanism of action of the agent. The invention is also directed an article of manufacture for characterizing a mechanism of action of a chemotherapeutic or genotoxic agent.Type: GrantFiled: December 16, 2011Date of Patent: June 20, 2017Assignee: Massachusetts Institute of TechnologyInventors: Hai Jiang, Justin Pritchard, Douglas A. Lauffenburger, Michael Hemann
-
Down-regulation of a homeodomain-leucine zipper I-class homeobox gene for improved plant performance
Patent number: 9677084Abstract: Methods for modulating plants using optimized ZmME293 down-regulation constructs are disclosed. Also disclosed are nucleotide sequences, constructs, vectors, and modified plant cells, as well as transgenic plants displaying increased seed and/or biomass yield, improved tolerance to abiotic stress such as drought or high plant density, improved nitrogen utilization efficiency, increased ear number and/or reduction in time to scenescence.Type: GrantFiled: April 23, 2012Date of Patent: June 13, 2017Assignee: PIONEER HI-BRED INTERNATIONAL, INC.Inventors: Mei Guo, Xiaomu Niu, Mary Rupe, Jeffrey Schussler -
Patent number: 9678061Abstract: The present invention relates to a method of identifying a target antigen of T cells comprising (a) contacting (aa) cells expressing (i) a functional T cell receptor complex comprising predefined matching T cell receptor ? and ? chains; and (ii) a read-out system for T cell activation; with (ab) antigen-presenting cells carrying (iii) peptide libraries encoded by randomised nucleic acid sequences; and (iv) MHC molecules recognised by the T cell receptor of (i); (b) assessing T cell activation using said read-out system; (c) isolating antigen-presenting cells that are in contact with the cells in which the read-out system indicates T cell activation; (d) identifying the target antigen or the nucleic acid molecule encoding said target antigen.Type: GrantFiled: August 5, 2011Date of Patent: June 13, 2017Assignee: Ludwig-Maximilians-Universität MünchenInventors: Klaus Dornmair, Reinhard Hohlfeld, Jorg Prinz, Katherina Siewert, Song-Min Kim
-
Patent number: 9677128Abstract: The present invention relates to methods and kits for the detection of 5-hydroxymethylcytosme (5hmC). In some embodiments, the present invention relates to methods and kits for detection of 5hmC in nucleic acid (e.g., DNA, RNA). In some embodiments, the present invention relates to detection of 5hmC in genomic DNA, e.g., mammalian genomic DNA.Type: GrantFiled: October 20, 2011Date of Patent: June 13, 2017Assignee: OSLO UNIVERSITETSSYKEHUS HFInventors: Adam Brian Robertson, John Arne Dahl, Arne Klungland
-
Patent number: 9662596Abstract: A method for breaking emulsions includes applying a polymer mixture to an emulsion. The emulsion can be energized, such as through centrifugation or vibration. In particular, the polymer mixture can be in liquid form. The polymer mixture includes first and second liquid polymer, the second liquid polymer being less hydrophilic than the first liquid polymer. Example polymer useful as the first or second liquid polymers includes polyether. In a water-in-oil emulsion, the less hydrophilic polymer can preferentially reside within the oil phase.Type: GrantFiled: October 30, 2014Date of Patent: May 30, 2017Assignee: LIFE TECHNOLOGIES CORPORATIONInventors: Ryan Jones, Maximilian Carpino
-
Patent number: 9663573Abstract: Methods and compositions for the treatment of liver conditions are provided, such methods and compositions comprising Notch2 antagonists, e.g., anti-Notch2 antibodies. Liver conditions include, but are not limited to, chronic liver disease.Type: GrantFiled: April 6, 2012Date of Patent: May 30, 2017Assignee: GENENTECH, INC.Inventors: Dorothy French, Christian W. Siebel, Erik Huntzicker
-
Patent number: 9657038Abstract: Guanidine-functionalized particles and methods of making and using such particles.Type: GrantFiled: November 20, 2013Date of Patent: May 23, 2017Assignee: 3M Innovative Properties CompanyInventors: George W. Griesgraber, Robert T. Fitzsimons, Jr., Douglas A. Hanggi, Masayuki Nakamura, Jerald K. Rasmussen
-
Patent number: 9655955Abstract: The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.Type: GrantFiled: December 10, 2015Date of Patent: May 23, 2017Assignee: CureVac AGInventors: Ingmar Hoerr, Florian Von Der Mülbe, Steve Pascolo
-
Patent number: 9656228Abstract: A method of making solid beads is disclosed, said method comprising: (i) providing a microfluidic device comprising a carrier fluid conduit and a functional fluid conduit which meet at a junction region; (ii) providing a laminar flow of a functional fluid comprising a solvent and a solute along the functional fluid conduit and providing a laminar flow of a carrier fluid along the carrier fluid conduit so as to form droplets of functional fluid in a flow of carrier fluid; (iii) cooling the segments of functional fluid in a conduit of the microfluidic device to form cooled (preferably frozen) droplets; and (iv) providing a liquid into intimate admixture with the cooled droplets so as to cause said solvent to exit said cooled droplets, thus forming solid beads. A microfluidic device for use in such a method is also disclosed.Type: GrantFiled: June 16, 2009Date of Patent: May 23, 2017Assignee: Midatech Pharma (Wales) LimitedInventors: Daniel Palmer, Richard Calder, Owen Shadick
-
Patent number: 9643998Abstract: Methods and systems for monitoring and/or controlling protein separation, purification, extraction, and/or fractionation processes are provided. The impedance of a protein mixture undergoing a protein process is measured and compared to a target reference impedance value or range of reference impedance values. If the measured impedance is not within an acceptable deviation of the target reference impedance value, a parameter of the protein mixture or process is adjusted.Type: GrantFiled: December 9, 2011Date of Patent: May 9, 2017Assignees: BAXALTA GMBH, BAXALTA INCORPORATEDInventors: Cary N. Wauters, Alexander Zaydenberg
-
Patent number: 9637800Abstract: The invention relates to a method for detecting the presence or absence of a bacterial pathogen in a biological sample obtained from a human or animal subject, using an internal control. In particular, the invention relates to a method for detecting the presence or absence of Streptococcus equi in an equine sample using a control bacterial strain as internal control for DNA extraction and PCR. The invention also relates to host cells (such as bacterial cells) and nucleic acids for use as internal standard in said method in addition to diagnostic kits comprising said host cells and nucleic acids.Type: GrantFiled: December 21, 2012Date of Patent: May 2, 2017Assignee: ANIMAL HEALTH TRUSTInventors: Colin Richard Barker, Katy Susan Webb, Andrew Stephen Waller
-
Patent number: 9618506Abstract: An assay method and device can perform at least one (e.g., at least two) assays on a single aliquot of a sample liquid. The device can mix a sample liquid with assay reagents including magnetically susceptible particles. The device is configured to create a sample liquid-air interface with the sample liquid. The magnetically susceptible particles can be located (via an applied magnetic field) at the liquid-air interface when a second liquid contacts the interface to form a liquid-liquid interface. The magnetic particles travel across the liquid-liquid interface to the second liquid. The magnetically susceptible particles are configured to transport an analyte across the interface into the second liquid. An assay for the analyte is performed in the second liquid. An assay for another analyte can also be performed in the sample liquid.Type: GrantFiled: March 29, 2007Date of Patent: April 11, 2017Assignee: INVERNESS MEDICAL SWITZERLAND GMBHInventors: Phillip Lowe, Steven Alexander Keatch, Steven Howell, Claus Marquordt, Ruth Polwart, Alan Kenneth Thomson
-
Patent number: 9618512Abstract: A method for the diagnosis of breast cancer using an anti-LAT1 monoclonal antibody. Among intraductal breast neoplastic lesions, duct carcinoma in situ, which is malignant, expresses LAT1 at a significantly high level, as compared to intraductal breast papilloma, which is benign. An anti-LAT1 monoclonal antibody is useful for the discrimination between these two lesions. Further, LAT1 is expressed at a high level in most of triple negative infiltrating carcinomas, which are negative for all of ER, PgR, and HER2 that are conventional molecular targeting markers for breast cancer. Therefore, LAT1 can be used as a novel molecular targeting marker for the triple negative breast cancer.Type: GrantFiled: April 13, 2012Date of Patent: April 11, 2017Assignee: J-Pharma Co., Ltd.Inventors: Hitoshi Endou, Isao Okayasu
-
Patent number: 9613254Abstract: The present disclosure relates to characterization of biological samples. By way of example, a biological sample may be contacted with a plurality of probes specific for targets in the sample, such as probes for immune markers and segmenting probes. Acquired image data of the sample may be used to segment the images into epithelial and stromal regions to characterize individual cells in the sample based on the binding of the probes. Further, the biological sample may be characterized by a heterogeneity of the characterized cells.Type: GrantFiled: September 30, 2015Date of Patent: April 4, 2017Assignee: General Electric CompanyInventors: Brion Daryl Sarachan, John Frederick Graf, Vidya Pundalik Kamath
-
Patent number: 9611512Abstract: Methods of identifying polymorphisms associated with ataxia-ocular apraxia 2 (AOA2), are described. The polymorphisms associated with AOA2 include specific mutations in the senataxin (SETX) gene. Also described are methods of diagnosis of AOA2, as well as methods of assessing an individual for carrier status for AOA2.Type: GrantFiled: July 11, 2014Date of Patent: April 4, 2017Assignee: ATHENA DIAGNOSTICS, INC.Inventors: Corey D. Braastad, Narasimhan Nagan, Jeffrey G. Jones, William K. Seltzer, Susan K. Allen, Sat Dev Batish, Hui Zhu
-
Patent number: 9611292Abstract: The 5-HT 2C receptor is implicated in feeding, obesity, palatable food reward, metabolic disorders, drug addiction, anxiety, stress sensitivity, and depression. Embodiments of the invention are directed to modulation of the 5-HT 2cR. Certain aspects are directed to therapies for the above referenced conditions. In certain aspects, therapeutic agents are identified that disrupt the 5-HT2cR:PTEN complex activating 5-HT2CR signaling. In certain aspects the complex is disrupted by a disrupter. The disrupter can be a peptide that displaces PTEN from the 5-HT 2cR:PTEN complex or inhibits the formation of the complex.Type: GrantFiled: April 27, 2012Date of Patent: April 4, 2017Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Kathryn Cunningham, Scott Gilbertson
-
Patent number: 9607091Abstract: An aspect includes generating an ontological domain based upon information elements, which elements represent aspects of detectable behaviors of an individual. A portion of the behaviors are captured via input of the individual, and another portion is received from a source that is independent of the computer and absent any user input. The generating includes creating subdomains of contextually organized collections of the information elements by topic, comparing the information elements across the subdomains, determining relationships of the information elements across topics based on common features, and determining relevance of the relationships across the subdomains based on measurable aspects of the information elements, whereby the relationships determined to be relevant are identified as an interest of the individual.Type: GrantFiled: February 11, 2016Date of Patent: March 28, 2017Assignee: AT&T INTELLECTUAL PROPERTY I, L.P.Inventor: Steven N. Tischer
-
Patent number: 9605319Abstract: Biomarkers and methods using the biomarkers for molecular detection and classification of disease and, particularly, molecular markers for cancer diagnosis and prognosis and methods of use thereof are provided.Type: GrantFiled: August 30, 2011Date of Patent: March 28, 2017Assignee: Myriad Genetics, Inc.Inventors: Steven Stone, Alexander Gutin, Susanne Wagner, Julia Reid
-
Patent number: 9597387Abstract: The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.Type: GrantFiled: November 29, 2012Date of Patent: March 21, 2017Assignee: Aridis Pharmaceuticals, Inc.Inventors: Simon Urwyler, Markus Haake, Michael Rodolf
-
Patent number: RE46559Abstract: In flow cytometry, particles (2) can be distinguished between populations (8) by combining n-dimensional parameter data, which may be derived from signal data from a particle, to mathematically achieve numerical results representative of an alteration (48). An alteration may include a rotational alteration, a scaled alteration, or perhaps even a translational alteration. Alterations may enhance separation of data points which may provide real-time classification (49) of signal data corresponding to individual particles into one of at least two populations.Type: GrantFiled: February 21, 2017Date of Patent: September 26, 2017Assignee: Beckman Coulter, Inc.Inventors: George C. Malachowski, Paul Barclay Purcell, Edward Allan Stanton, Kenneth Michael Evans